MICROBPLEX, INC.

Medtech · Defunct

MENSA diagnostic platform that isolates circulating antibody-secreting cells from blood and cultures them to detect pathogen-specific antibodies for early Lyme disease diagnosis

Grants
$895K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$289K
2 awards · Health and Human S
#431 of 4531 in medtech
Patents
4
1 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Health and Human Services · Lab Supplies$139,200
Federal contractDepartment of Health and Human Services · SBIR Phase I Topic OO6 Igf::ot::igf$149,999
Federal grantDepartment of Health and Human Services · Phase I · Novel Diagnostics for Early Lyme Disease$596,428
Federal grantDepartment of Health and Human Services · Phase I · Novel Diagnostics for Early Lyme Disease$298,875
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
428ACOUSTICABIO, INC.$295K—
429EIGEN HEALTH SERVICES LLC$294K—
430NEXOGEN INC$293K—
431MICROBPLEX, INC.$289K—
432BDYWR, LLC$275K—
433JBS SCIENCE INC$274K—
434HYDROCISION INC$252K$6.2M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 4

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.